Although the interaction between CCL22 and its receptor CCR4 may recruit regulatory T cells (Tregs) into the TME, thereby bolstering tumor immune evasion, it also fosters the infiltration of anticancer tumor-infiltrating lymphocytes (TILs), presenting a dual effect (29). Here, CCL22 is linked to neoplasm.